Decheng Capital LLC reported 14 holdings worth US$732M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Decheng Capital LLC reported 14 holdings worth US$732M as of Jun 30, 2026. Largest: Cg Oncology, Inc., Nuvation Bio Inc. and Aardvark Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 14
- Value as reported
- US$732M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Cg Oncology, Inc. | 6.37M | US$453M | 61.9% |
| Nuvation Bio Inc. | 26M | US$147M | 20.1% |
| Aardvark Therapeutics, Inc. | 3.92M | US$22.6M | 3.1% |
| Aclaris Therapeutics, Inc. | 4.04M | US$21.4M | 2.9% |
| Upstream Bio, Inc. | 2.72M | US$18.9M | 2.6% |
| Arcus Biosciences, Inc. | 465K | US$14.3M | 2.0% |
| Equillium, Inc. | 4.45M | US$14.2M | 1.9% |
| Revolution Medicines, Inc. | 52,667 | US$9.86M | 1.3% |
| Beyondspring, Inc. | 3.8M | US$6.65M | 0.91% |
| Zentalis Pharmaceuticals, Inc. | 1.32M | US$6.42M | 0.88% |
| Pyxis Oncology, Inc. | 327K | US$984K | 0.13% |
| Tango Therapeutics, Inc. | 20,000 | US$625K | 0.09% |
| Krystal Biotech, Inc. | 0 | US$0 | 0.00% |